Please assess the completion status of the following clinical trial:

Trial Title: A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female participants of age 18 to 55 years.~* Females must have a negative pregnancy test.~* Have a Body Mass Index (BMI) of ≥ 18 and ≤ 29.9 kg/m\^2.~Exclusion Criteria:~* History or presence of any clinically significant disease or disorder.~* History or presence of gastrointestinal, hepatic or renal disease, or any other condition (including gastrointestinal surgery) known to interfere with absorption, distribution, metabolism, or excretion of drugs.~* History of acute or chronic pancreatitis.~* Family history of sudden cardiac death before the age of 50 of a first-degree relative.~* History of additional risk factors for Torsade de Pointes (eg, heart failure, clinically important bradycardia and electrolyte disturbances eg, hypokalemia, hypocalcemia, hypomagnesemia or family history of long QT syndrome).~* History of neoplastic disease~* Any clinically significant abnormalities in clinical chemistry, hematology, urinalysis results or vital signs.~* Any clinically significant abnormalities in rhythm, conduction, or morphology of the 12-lead resting electrocardiogram (ECG).~* Any positive result on screening for serum hepatitis B surface antigen OR anti-HBc antibody, indicative of active hepatitis B (ie, participants with positive anti-HBc antibody result are acceptable if anti HBc IgM antibodies are negative), hepatitis C antibody, and Human immunodeficiency virus (HIV) antibody.~* Current smokers or those who have smoked or used nicotine products (including e-cigarettes).~* Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.~* Use of drugs with enzyme-inducing properties such as St John's Wort.~* Participant has a positive test result for SARS-CoV-2 RT-PCR during screening period or at baseline.~* Participant has clinical signs and symptoms consistent with COVID-19 or a history of severe COVID-19 (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Participants will receive cotadutide and will receive a single dose of moxifloxacin-placebo on Day 1 and Day 93.
- Arm 2A (Type: EXPERIMENTAL): Participants will receive a single dose of moxifloxacin (Day 1) prior to initiating treatment with cotadutide-placebo for up to 13 weeks, followed by a single dose of moxifloxacin-placebo on Day 93.
- Arm 2B (Type: EXPERIMENTAL): Participants will receive a single dose of moxifloxacin-placebo (Day 1) prior to initiating treatment with cotadutide-placebo for up to 13 weeks, followed by a single dose of moxifloxacin on Day 93.

Based on this trial design, predict the completion outcome and termination type (if applicable).